<DOC>
	<DOC>NCT00151437</DOC>
	<brief_summary>The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.</brief_summary>
	<brief_title>Canadian Pegvisomant Compassionate Study In Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<criteria>Subjects must have participated and completed the previous Pegvisomant studies or have shown to be unresponsive to other conventional therapies ALT/AST&gt;3 times the ULN or have hepatic disease have severe visual field loss, cranial nerve palsies or intracranial HTN that requires surgery to decompress the tumor unwilling to selfadminister the medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>